Wang et al. (2023)
- Authors: Ping-Yuan Wang, Jin Ma, Young C. Kim, Ah-Young Son, Adnan M. Syed, Chengyu Liu, Marco P. Mori, Richard D. Huffstutler, Jennifer L. Stolinski, S. Lalith Talagala, Joo-Gwang Kang, Brian Walitt, Avindra Nath, Paul M. Hwang
- Institutes: Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
- Publisher: Proceedings of the National Academy of Sciences (PNAS)
- Link: DOI
Summary
This landmark study identifies a specific molecular mechanism where cellular stress leads to the production of a protein called WASF3, which directly
What was researched?
The researchers investigated whether elevated levels of the WASF3 protein contribute to mitochondrial dysfunction and the characteristic exercise intolerance observed in ME/CFS.
Why was it researched?
While ME/CFS is defined by profound fatigue and post-exertional malaise, the underlying biological
How was it researched?
The team conducted a detailed case study of a patient with severe fatigue, followed by experiments using cell cultures and genetically engineered mice. They also analyzed muscle biopsy samples from a cohort of 14 ME/CFS patients and 10 healthy controls to validate their findings in a broader clinical context.
What has been found?
The study found that WASF3 is induced by the unfolded protein response (ER stress) and physically disrupts the assembly of mitochondrial supercomplexes, which are critical for oxygen consumption and energy production. Reducing WASF3 levels or treating cells with salubrinal 💊 or tauroursodeoxycholic acid (TUDCA) 💊 significantly improved mitochondrial function. Furthermore, most ME/CFS patients in the cohort showed substantially higher levels of WASF3 in their muscle tissue compared to healthy individuals.
Discussion
The findings suggest that the interaction between ER stress and mitochondrial failure creates a ‘bioenergetic bottleneck’ in ME/CFS. While the initial trigger for this stress remains unknown, the identification of WASF3 as the mediator provides a tangible target for drug development.
Conclusion & Future Work
Targeting the WASF3 pathway or the associated ER stress response may offer a novel therapeutic strategy to alleviate exercise intolerance in ME/CFS and other chronic fatigue-related conditions.